We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Picankibart is a recombinant anti-interleukin 23p19 ...

Eli Lilly and Company (NYSE: LLY) is one of the best growth stocks to buy for the next 20 years. On February 18, Eli Lilly ...

Combination ixekizumab plus tirzepatide outperformed ixekizumab monotherapy for the treatment of both psoriasis and overweight or obesity, according to topline results announced by Eli ...

Botulinum toxin A (BoNT-A) exhibited promising results for nail psoriasis for up to 6 months with a single injection. Botulinum toxin A (BoNT-A) injection emerged as an effective therapy for patients ...

The webinar will be broadcast via Zoom. Interested participants can register using the following LINK. The discussion will provide an in-depth exploration of the plaque psoriasis landscape, current ...

The results of 2 recent clinical trials combining the GLP-1 drug and the biologic reinforce the benefits of treating obesity and inflammation together.

Concomitant ixekizumab and tirzepatide significantly improved skin clearance and weight reduction in adults with moderate to severe plaque psoriasis.

SAN FRANCISCO and SUZHOU, China, Dec. 8, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

NEW YORK (Reuters Health) - Injections of a protein called interleukin-4 (IL-4) seem equal to the best therapy now available for relieving symptoms of the chronic skin condition psoriasis, the results ...

At 36 weeks in the TOGETHER-PsO study, concomitant Taltz and Zepbound met primary endpoint of superiority vs. Taltz monotherapy in achieving complete skin clearance ...

Despite recent significant advances in systemic therapies for psoriasis, topical treatment retains a prominent role for many patients. The American Academy of Dermatology/National Psoriasis Foundation ...